HK Stock Market Move | ASCLETIS-B(01672) now up more than 4%. Subcutaneous injection of the glucagon-like peptide-1 receptor agonist ASC36 has entered the clinical development stage.

ASCLETIS-B (01672) rose by more than 4%, reaching a 4.62% increase at the time of publication, trading at 9.74 Hong Kong dollars, with a turnover of 12.814 million Hong Kong dollars. In terms of news, Gilead Sciences announced that they have selected a potential best-in-class monthly subcutaneous injection of amylin receptor agonist ASC36 as a clinical development candidate. Gilead expects to submit an Investigational New Drug Application (IND) to the US Food and Drug Administration (FDA) for ASC36 for the treatment of obesity in the second quarter of 2026. ASC36 is a peptide agonist of the amylin receptor developed independently by Gilead through structure-based AI-assisted drug discovery and ultra-long-acting drug development platform technology. The designed and optimized ASC36 achieves a longer apparent half-life (time required for blood drug concentration to decrease to 50% of Cmax) and higher bioavailability per milligram of peptide, supporting monthly subcutaneous administration with an injection volume of no more than 1 milliliter. These designed and optimized features make it more cost-effective in large-scale production.